Montag & Caldwell LLC Sells 1,285 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Montag & Caldwell LLC lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,787 shares of the medical research company's stock after selling 1,285 shares during the quarter. Thermo Fisher Scientific makes up about 1.6% of Montag & Caldwell LLC's holdings, making the stock its 24th biggest holding. Montag & Caldwell LLC's holdings in Thermo Fisher Scientific were worth $7,693,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Barrett & Company Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth $28,000. FPC Investment Advisory Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $28,000. Missouri Trust & Investment Co bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Pillar Financial Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Finally, Endeavor Private Wealth Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter worth $30,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMO has been the subject of a number of recent research reports. Royal Bank of Canada set a $693.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. Citigroup decreased their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Scotiabank increased their price objective on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research note on Monday, February 3rd. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target on the stock in a research report on Friday, January 10th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $642.67.

Thermo Fisher Scientific Trading Down 2.4 %

NYSE TMO traded down $10.68 on Friday, reaching $426.11. The company had a trading volume of 3,037,150 shares, compared to its average volume of 1,715,026. Thermo Fisher Scientific Inc. has a fifty-two week low of $409.85 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm has a market cap of $160.85 billion, a price-to-earnings ratio of 25.78, a P/E/G ratio of 2.99 and a beta of 0.86. The business has a 50 day moving average of $497.67 and a two-hundred day moving average of $533.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio is currently 10.41%.

Insiders Place Their Bets

In other news, CFO Stephen Williamson sold 9,825 shares of the business's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.